###### Summary box

​What is already known on this subject?
=======================================

-   Colorectal cancer (CRC) is a global public health challenge. A large number of genetic association studies have been conducted to assess the potential correlation between common genetic variations and CRC risk.

​What are the new findings?
===========================

-   Using an established framework for grading credibility of genetic associations, we classified 14 independent variants at 12 loci (*MUTYH, SMAD7, TERT, CDH1, RHPN2, BMP2, TGFB1* and common variants tagging loci at 8q24, 8q23.3, 10p14, 11q23.1, 20p12.3) as highly credibly associated with CRC risk. A total of 63 variants at 52 loci were classified as 'less-credible positive' SNPs; variants of nine of these genes could be mostly highly prioritised for further investigation. For 231 variants previously reported to be associated with CRC, our meta-analyses found no evidence to support such associations.

​How might it impact on clinical practice in the foreseeable future?
====================================================================

-   This database will be helpful for future research by promoting the investigation of these variants and corresponding genetic loci in populations other than of European origin, serving as a genetic basis for predicting risk estimates for population groups and providing candidate genes for further functional studies or gene-environment interaction studies.

Introduction {#s1}
============

Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies and the leading cause of cancer deaths in the world, with 1.65 million new cases and about 835 000 deaths in 2015.[@R1] The global burden of CRC is expected to increase by 60%, with more than 2.2 million new cases and almost 1.1 million deaths occurring annually by 2030.[@R2] The distribution of CRC global burden varies widely, with more than two-thirds of all cases and about 60% of all deaths occurring in countries with a high or very high human development index, including Australia and New Zealand, Europe and North America, while incidence and mortality rates in Africa and South-Central Asia are relatively low.[@R1] These geographic differences appear to be attributable to the differences in both environmental exposures and the background of genetically determined susceptibility.[@R3]

It is estimated that 15%--25% of CRC risk variance is attributed to inherited genetic factors, and the first-degree relatives of CRC patients have two to four times higher risk of developing CRC.[@R4] The inherited genetic risk of CRC can be partly accounted for by a combination of rare high-penetrance mutations and large numbers of common genetic variants each conferring small risk.[@R6] Although a number of highly penetrant mutations (eg, DNA mismatch repair genes, *APC*, *SMAD4*, *LKB1/STK11*, *MUTYH*) have been identified to influence CRC susceptibility with large effects, overall they account for only 2%--5% of incident CRC cases in the general population because these mutations are very rare.[@R7] Candidate gene association studies have investigated the role of a large number of common genetic variants in CRC risk, but only a small number of them have been successfully replicated in subsequent studies.[@R10]

In 2012 and 2014, we reported two independently conducted series of meta-analyses to systematically evaluate associations between CRC and common variants using data from candidate gene studies and genome-wide association studies (GWASs) and identified a number of promising genetic risk variants for CRC risk.[@R10] Our first field synopsis (published in 2012) reported 16 variants in 13 independent loci (*MUTYH, MTHFR, SMAD7, 8q24, 8q23.3, 11q23.1, 14q22.2, 1q41, 20p12.3, 20q13.33, 3q26.2, 16q22.1, 19q13.1*),[@R10] and the second field synopsis (published in 2014) identified 8 additional variants in 5 independent loci (*APC, CHEK2, DNMT3B, MLH1, MUTYH*) that were strongly associated with CRC.[@R11] These two synopses used slightly different methodologies, in that the 2012 field synopsis only included variants reported in four or more studies in meta-analyses, whereas the 2014 included variants with three or more studies, and there were some differences in the criteria applied for the evidence appraisal.[@R10]

In this study, we aimed to perform an updated field synopsis for CRC risk by including the most recently published genetic association studies, by following established guidelines[@R12] and using harmonised methods for evidence appraisal.[@R14] We systematically captured all published genetic association data on CRC for meta-analyses and subsequently incorporated data from GWAS consortia for interrogation. This study provides an up-to-date and publicly available database for CRC genetics (CRCgene2) and presents these data within a defined statistical and causal inference framework to aid interpretation of the results.[@R13] We aimed to provide new insights into the fundamental biological mechanisms involved in colorectal carcinogenesis.

Methods {#s2}
=======

Literature search and data collection {#s2-1}
-------------------------------------

To identify genetic association studies of CRC risk, we searched the Medline database via the Ovid gateway and the search terms comprising medical subject headings (MeSH) and keywords relating to colorectal neoplasms, the MeSH heading 'genetic predisposition to disease', and the keywords 'gene\$' and 'associate\$' were applied to terms in the entire article. The latest literature search was performed on 21 November 2018. We screened the eligibility of retrieved publications in a three-step parallel review of title, abstract and full text by following the predefined inclusion and exclusion criteria. Thus, each eligible study evaluated the association between a polymorphic genetic variant (with minor allele frequency ≥0.01 in the reference panel of the 1000 genomes) and a sporadic CRC. Studies investigating only premalignant conditions such as adenomas, polyps or dysplastic tissue were excluded. Studies investigating hereditary CRC syndromes, such as familial adenomatous polyposis, hereditary non-polyposis CRC, juvenile polyposis syndrome and Gardner's syndrome; solely focusing on the progression or histological phenotype of CRC; or studies in animals; were excluded. Case-control, cohort and GWASs were included, while family-based studies were excluded. All included studies were published in English in a peer-reviewed journal; studies only reported as conference abstracts were excluded. Data from the eligible studies were abstracted into two standardised tables, including the key variables with regard to the study identifiers and context, study design and limitations, genotype information and outcome effects.

A list of genetic variants that were investigated in meta-analyses was summarised and data from three GWAS consortia (Scotland, Canada and Spain) were incorporated for meta-analyses, when the genotype data are available for the listed variants. In brief, the Study of CRC in Scotland (SOCCS) is a population-based case-control GWAS that includes 3417 cases and 3500 controls. The Assessment of Risk for Colorectal Tumors In Canada (ARCTIC) is a case-control GWAS database that includes 1231 cases and 1240 controls. The population-based cohort study in Spain comprised two phases (EPICOLON I and EPICOLON II) adding up to 2000 cases and 2000 controls. Restricted candidate gene genotyping data were available from both phases and GWAS data were only accessible from 881 cases and 667 controls from phase 2.[@R17] More details about these GWAS datasets are present in [online supplementary text](#SP1){ref-type="supplementary-material"}.
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Statistical analysis {#s2-2}
--------------------

Meta-analysis was performed for genetic variants with data available from at least three independent studies. Summary crude ORs and 95% CI for allelic, recessive and dominant genetic models were calculated by applying either the fixed-effect model (Mantel-Haenszel method) or the random-effects model (DerSimonian-Laird method) in case of the existence of substantial heterogeneity. The Q statistic (with a threshold of p value \<0.05) and I^2^ metric were calculated to quantify between-study heterogeneity. Funnel plot analysis with an Egger test was conducted to test for small study effects. We also estimated the statistical power of each meta-analysis based on the significance level of α=0.05, the effect sizes and the allele frequencies of genetic variants (an integral component of the Bayesian False-Discovery Probability (BFDP) analysis).[@R19] All statistical analysis was conducted by using R software (R x64 3.1.0).

Credibility of the identified genetic associations {#s2-3}
--------------------------------------------------

We first applied the BFDP[@R19] and the Venice criteria[@R12] to assess the credibility of any observed genetic associations with p\<0.05 in at least one genetic model. We then validated these associations in three additional GWAS consortia: Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO),[@R20] Colorectal Transdisciplinary Study (CORECT, <https://research.fhcrc.org/peters/en/corect-study.html>) and Colon Colorectal Cancer Family Registry (CFR).[@R21] With meta-analysis of these three GWAS datasets, we validated the observed genetic associations using data from 58 131 CRC cases and 67 347 controls ([online supplementary text](#SP1){ref-type="supplementary-material"}), and the statistical power of validation was estimated accordingly.

The BFDP assesses the noteworthiness of an observed association. The BFDP was selected rather than the false-positive report probability (FPRP) because it uses more information, defines the noteworthiness threshold explicitly in terms of the costs of false discovery and non-discovery, and does not suffer from the inferential limitations identified for the FPRP.[@R22] We calculated BFDP values at two levels of prior probability: a medium/low prior level (0.05 to 10^−3^), close to what would be expected for a candidate gene, and a very low prior level (10^−4^ to 10^−6^), close to what would be expected for a random SNP. A noteworthy threshold was defined as 0.2 based on the assumption that the cost of false discovery would be four times higher than that of false non-discovery.[@R19]

According to the Venice criteria, the credibility of associations is assessed for three aspects: the amount of evidence, the extent of replication and the protection from bias.[@R12] We used statistical power to assess the volume of evidence and a grade of A, B and C was assigned, respectively, when statistical power was greater than 80%, 50%--79% or less than 50%. The extent of replication was assessed by the measurement of heterogeneity (I^2^ criterion), and a grade of A, B and C was assigned, respectively, when I^2^ was less than 25%, 25%--49% or greater than 50%.[@R12] For protection from bias, a complete assessment is difficult; instead, we considered the following aspects: (1) the phenotype definition was addressed by our inclusion criteria---namely that cases would have newly incident CRC; (2) genotyping error rates are generally low; (3) the criterion of replication across studies in part addresses potential concerns about variation in genotyping quality between studies; and (4) the magnitude of effect of population stratification appears to be small in general.[@R23]

Genetic associations were then classified into four categories based on the following criteria. Associations were classified as 'positive' if they: (1) were statistically significant at a p value level of 0.05 in at least two of the genetic models, (2) had a BFDP less than 0.20 at least at the p value level of 0.05, (3) had a statistical power greater than 80%, (4) had an I^2^ less than 50%. A class of 'less-credible positive', with a less-stringent threshold, was assigned to the associations (1) that were statistically significant at a p value threshold of 0.05 in at least one of the genetic models, but (2) their BFDP was greater than 0.20 or their statistical power was between 50% and 79% or had an I^2^ greater than 50%. Associations with p value large than 0.05 were further classified as 'null' or 'negative' by assessing if there are more than 5000 cases. After credibility assessment, genetic variants classified as 'positive' and 'less-credible positive' were sent to the CORECT coordinating centre to validate their associations with CRC risk using additive, dominant and recessive models. At this stage, 'positive' associations that failed to be validated (at p\<0.05) were downgraded to 'less-credible positive'. A schematic diagram is shown in [figure 1](#F1){ref-type="fig"} to demonstrate datasets included in each phase of the analysis.

![Diagram of the study design. ARCTIC, Assessment of Risk for Colorectal Tumors In Canada; BFDP, Bayesian False-Discovery Probability; CFR, Colorectal Cancer Family Registry; CORECT, Colorectal Transdisciplinary Study; CRC, colorectal cancer; EPICOLON, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association; GECCO, Genetics and Epidemiology of Colorectal Cancer Consortium; GWASs, genome-wide association studies; SOCCS, Study of CRC in Scotland.](gutjnl-2019-319313f01){#F1}

Results {#s3}
=======

Literature search and data collection {#s3-1}
-------------------------------------

A total of 20 900 citations were identified from literature search. Of these, 6770 (32.4%) papers were published after the search period of the most recent field synopsis (31 December 2012).[@R11] After eligibility screening, we finally included and extracted data from 869 publications ([figure 2](#F2){ref-type="fig"}), reporting the association of CRC risk with 1063 polymorphisms in 303 different genes, of which 308 polymorphisms were reported in at least three independent studies.

![The distribution of included studies published from 1991 to 2018.](gutjnl-2019-319313f02){#F2}

Meta-analyses {#s3-2}
-------------

Meta-analyses were conducted for 308 polymorphisms in 158 different loci with data available in three or more candidate or GWA studies ([online supplementary table 1](#SP2){ref-type="supplementary-material"}). On average, these meta-analyses were based on 6149 CRC cases (median; IQR=2301--7334) and 7337 controls (median; IQR=2809--8885) originating from 8 (median; IQR=4--9) case--control studies. Data from the Scottish, Canadian and/ or Spanish GWAS were incorporated in the meta-analyses for 132 SNPs. Summary crude ORs and 95% CI for the allelic, dominant and recessive models are presented in [table 1](#T1){ref-type="table"}. Of the meta-analyses for 308 polymorphisms (tagged at different 158 loci), a total of 77 SNPs (25.6%) (tagged in 61 different loci) were identified to have a nominally statistically significant association (p value \<0.05) with CRC risk in at least one of the three genetic models and were eligible for credibility assessment using the BFDP[@R19] ([online supplementary tables 2--4](#SP2){ref-type="supplementary-material"}) and the Venice criteria[@R12] and for validation in the three (GECCO, CORECT and CCFR) GWAS consortia ([online supplementary tables 5--7](#SP2){ref-type="supplementary-material"}).
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###### 

Summary of 'credible positive associations' from meta-analyses and credibility assessment

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene        Variant      Cases vs controls\        Allelic model   Power                 Recessive model: var/var vs wt/wt and wt/var   Dominant model: wt/var and var/var vs wt/wt   Classification                                                                                                                                                      
                           (number of samples)                                                                                                                                                                                                                                                                                                              
  ----------- ------------ ------------------------- --------------- --------------------- ---------------------------------------------- --------------------------------------------- ---------------- ------ ---- --------------------- ---------- -------------- ------- ------ ---- --------------------- ---------- --------------- ---------- ------ ----------
  *MUTYH*     rs36053993   28 302 vs 20 935 (19\*)   19              1.42 (1.22 to 1.66)   4.89E-06                                       0 (0 to 33)                                   0.703            0.99   na   na                    na         na             na      na     19   1.31 (1.12 to 1.53)   0.001      0 (0 to 24)     0.837      0.88   Positive

  *MUTYH*     rs34612342   28 180 vs 20 923 (19\*)   17              1.89 (1.47 to 2.42)   5.72E-07                                       0 (0 to 62)                                   0.828            1.00   7    3.40 (1.22 to 9.48)   0.019      0 (0 to 0)     0.998   1.00   17   1.80 (1.39 to 2.31)   6.42E-06   0 (0 to 52)     0.884      1.00   Positive

  *SMAD7*     rs12953717   28 006 vs 26 539 (13\*)   13              1.11 (1.07 to 1.16)   6.24E-07                                       49 (0 to 93)                                  0.024            1.00   13   1.17 (1.08 to 1.26)   8.34E-05   45 (0 to 94)   0.041   1.00   13   1.14 (1.07 to 1.21)   5.00E-05   54 (10 to 95)   0.020      1.00   Positive

  *SMAD7*     rs4464148    17 772 vs 17 356 (9\*)    9               1.12 (1.08 to 1.16)   2.66E-09                                       12 (0 to 92)                                  0.337            1.00   9    1.13 (1.00 to 1.28)   0.054      49 (0 to 98)   0.047   0.97   9    1.16 (1.11 to 1.21)   2.09E-10   2 (0 to 86)     0.416      1.00   Positive

  *8q24*      rs10505477   18 562 vs 20 132 (14)     14              1.14 (1.10 to 1.19)   2.04E-11                                       44 (0 to 82)                                  0.040            1.00   14   1.16 (1.10 to 1.23)   4.06E-07   35 (0 to 74)   0.092   1.00   14   1.24 (1.17 to 1.32)   1.04E-11   36 (0 to 81)    0.084      1.00   Positive

  *20p12.3*   rs961253     22 971 vs 25 270 (14\*)   14              1.11 (1.06 to 1.16)   1.58E-05                                       60 (28 to 91)                                 0.002            1.00   13   1.14 (1.06 to 1.22)   7.10E-04   36 (0 to 96)   0.098   1.00   14   1.14 (1.07 to 1.21)   4.75E-05   57 (21 to 88)   0.004      1.00   Positive

  *8q23.3*    rs16892766   8351 vs 8878 (6\*)        6               1.24 (1.15 to 1.34)   1.67E-08                                       4 (0 to 92)                                   0.393            0.99   6    1.21 (0.88 to 1.67)   0.240      0 (0 to 85)    0.747   0.22   6    1.27 (1.17 to 1.38)   4.00E-09   3 (0 to 90)     0.400      1.00   Positive

  *10p14*     rs10795668   16 763 vs 18 302 (16\*)   16              0.88 (0.83 to 0.94)   4.35E-05                                       67 (34 to 89)                                 6.94E-05         1.00   16   0.83 (0.77 to 0.89)   4.77E-07   11 (0 to 70)   0.332   1.00   16   0.85 (0.79 to 0.93)   2.27E-04   68 (34 to 87)   3.06E-05   1.00   Positive

  *11q23.1*   rs3802842    22 320 vs 22 965 (20\*)   20              1.15 (1.11 to 1.20)   5.21E-12                                       43 (0 to 78)                                  0.024            1.00   20   1.24 (1.13 to 1.35)   3.62E-06   45 (5 to 86)   0.017   1.00   20   1.19 (1.13 to 1.25)   7.22E-12   33 (0 to 70)    0.075      1.00   Positive

  *BMP2*      rs355527     13 539 vs 14 375 (9)      9               1.12 (1.08 to 1.17)   1.65E-10                                       0 (0 to 0)                                    0.977            0.99   9    1.18 (1.09 to 1.27)   3.54E-05   0 (0 to 94)    0.458   0.99   9    1.16 (1.10 to 1.21)   2.43E-09   0 (0 to 9)      0.966      1.00   Positive

  *CDH1*      rs1862748    17 436 vs 18 418 (11)     11              0.91 (0.88 to 0.94)   1.98E-08                                       0 (0 to 63)                                   0.703            0.98   11   0.83 (0.77 to 0.90)   1.59E-06   2 (0 to 68)    0.427   1.00   11   0.91 (0.87 to 0.95)   6.31E-06   0 (0 to 70)     0.511      0.99   Positive

  *RHPN2*     rs7259371    15 762 vs 16 700 (9\*)    9               0.87 (0.82 to 0.93)   1.65E-05                                       52 (0 to 90)                                  0.034            1.00   9    0.85 (0.73 to 0.98)   0.027      17 (0 to 86)   0.295   0.71   9    0.86 (0.80 to 0.92)   3.81E-06   42 (0 to 87)    0.084      1.00   Positive

  *TERT*      rs2736100    16 176 vs 18 135 (8)      8               1.07 (1.04 to 1.10)   2.95E-05                                       0 (0 to 82)                                   0.526            0.88   8    1.06 (1.00 to 1.13)   0.069      15 (0 to 86)   0.316   0.64   8    1.13 (1.08 to 1.20)   2.03E-06   0 (0 to 64)     0.788      1.00   Positive

  *TGFB1*     rs1800469    4021 vs 6024 (10)         10              0.89 (0.80 to 0.99)   0.036                                          53(2t o 92)                                   0.023            1.00   10   0.84 (0.74 to 0.94)   0.003      0 (0 to 75)    0.527   1.00   10   0.84 (0.71 to 1.00)   0.051      58 (15 to 92)   0.011      1.00   Positive
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Includes GWAS data from SOCCS.

GWASs, genome-wide association studies; SOCCS, Study of CRC in Scotland.

Credibility assessment indicated 18 variants (5.8% of the meta-analysed SNPs) tagging 16 loci (rs36053993 and rs34612342 in *MUTYH,* rs2066847 in *NOD2,* rs12953717 and rs4464148 in *SMAD7,* rs1569686 in *DNMT3B,* rs2736100 in *TERT,* rs9858822 in *PPAR-gamma,* rs1862748 in *CDH1,* rs7259371 in *RHPN2,* rs355527 in *BMP2,* rs1800469 in *TGFB1*, rs10505477 in 8q24, rs16892766 in 8q23.3, rs3802842 in 11q23.1, rs961253 in 20p12.3, rs10795668 in 10p14, rs4951291 in 1q32.1) had the most credible associations with CRC risk and are therefore referred to as 'positive' SNPs ([table 1](#T1){ref-type="table"}, [online supplementary tables 2--4](#SP2){ref-type="supplementary-material"}). These findings are based on accrued data on 1224 to 43 652 cases and on 1381 to 60 883 controls, with a median of 17 100 cases per meta-analysis. The linkage disequilibrium (LD) between these 'positive' polymorphisms was checked pairwise using the Ensembl LD calculator with reference to the 1000 genomes: phase 3 CEU population and we found two pairs of SNPs (rs355527 and rs961253, rs12953717 and rs4464148) with r^2^ \>0.20 ([online supplementary tables 8](#SP2){ref-type="supplementary-material"}). The other 59 variants (19.2% of the meta-analysed SNPs) in 49 loci with p value \<0.05 were classified as 'less-credible positive' SNPs, given high heterogeneity, low statistical power or a high possibility of being false positive (BFDP \>0.2) for their association with CRC risk ([table 2](#T2){ref-type="table"}, [online supplementary tables 2--4](#SP2){ref-type="supplementary-material"}). The summary findings for 'less-credible positive' SNPs were based on accrued data on 246 to 51 730 CRC cases and on 399 to 53 589 controls, with a median of at least 4287 CRC cases per meta-analysis.

###### 

Summary of 'less-credible associations' from meta-analyses and credibility assessment

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene               Variant        Cases vs controls\         Allelic model                         Recessive model: var/var vs wt/wt and wt/var   Dominant model: wt/var and var/var vs wt/wt   Classification                                                                                                                                                           
                                    (number of samples)                                                                                                                                                                                                                                                                                                                    
  ------------------ -------------- -------------------------- --------------- --------------------- ---------------------------------------------- --------------------------------------------- ---------------- ------ ---- ---------------------- ---------- --------------- ---------- ------ ---- --------------------- ---------- --------------- ---------- ------ ---------------
  *MTHFR*            rs1801133      43 652 vs 60 883 (94\*†)   91              0.96 (0.93 to 0.99)   8.79E-03                                       53 (59 to 85)                                 3.61E-09         0.84   93   0.87 (0.81 to 0.93)    7.36E-05   56 (63 to 86)   6.79E-11   1.00   93   0.98 (0.94 to 1.02)   0.249      48 (52 to 82)   1.98E-07   0.36   Less credible

  *miR*              rs895819       1322 vs 1641 (4)           4               1.18 (1.06 to 1.32)   0.003                                          4 (0 to 95)                                   0.373            0.09   4    1.50 (1.23 to 1.83)    6.32E-05   1 (0 to 96)     0.385      0.44   4    1.08 (0.93 to 1.26)   0.302      0 (0 to 94)     0.474      0.05   Less credible

  *ADH1B*            rs1229984      4449 vs 6995 (9)           9               1.05 (0.94 to 1.18)   0.401                                          57 (8 to 91)                                  0.018            0.16   9    1.23 (1.02 to 1.48)    0.028      0 (0 to 70)     0.493      0.68   9    1.04 (0.90 to 1.20)   0.595      60 (14 to 92)   0.010      0.11   Less credible

  *XRCC1*            rs25487        13 017 vs 18 166 (37)      37              1.11 (1.03 to 1.19)   0.008                                          71 (68 to 90)                                 8.64E-12         0.74   36   1.17 (1.02 to 1.34)    0.025      59 (39 to 80)   3.14E-06   0.91   37   1.11 (1.01 to 1.21)   0.023      63 (58 to 89)   1.44E-07   0.88   Less credible

  *HFE*              rs1800562      6547 vs 34 156 (10‡)       10              1.10 (1.01 to 1.20)   0.035                                          0 (0 to 40)                                   0.850            0.46   10   1.15 (0.69 to 1.92)    0.582      24 (0 to 84)    0.240      0.12   10   1.10 (1.01 to 1.21)   0.037      0 (0 to 25)     0.937      0.68   Less credible

  *MTHFR*            rs1801131      23 523 vs 35 193 (57\*)    57              0.98 (0.95 to 1.01)   0.258                                          22 (0 to 57)                                  0.075            0.19   57   0.91 (0.84 to 0.98)    0.010      23 (0 to 62)    0.064      0.94   57   1.00 (0.96 to 1.04)   0.970      10 (0 to 48)    0.270      0.50   Less credible

  *CYP2C9*           rs1799853      9588 vs 11 428 (12)        12              0.95 (0.90 to 1.01)   0.086                                          0 (0 to 73)                                   0.530            0.26   12   1.16 (0.96 to 1.40)    0.127      0 (0 to 73)     0.667      0.39   12   0.93 (0.87 to 0.99)   0.015      0 (0 to 72)     0.452      0.65   Less credible

  *CRP*              rs1800947      2853 vs 3381 (3)           2               1.03 (0.88 to 1.20)   0.745                                          0 (0 to 100)                                  0.334            0.10   2    3.95 (1.35 to 11.56)   0.012      7 (0 to 99)     0.301      1.00   3    0.96 (0.82 to 1.12)   0.604      0 (0 to 81)     0.911      0.08   Less credible

  *CRP*              rs1205         3037 vs 9333 (4)           4               1.07 (1.00 to 1.15)   0.065                                          0 (0 to 95)                                   0.479            0.34   4    1.18 (1.02 to 1.37)    0.027      0 (0 to 94)     0.431      0.73   4    1.05 (0.96 to 1.16)   0.288      0 (0 to 90)     0.669      0.21   Less credible

  *EGF*              rs4444903      899 vs 976 (5)             5               0.83 (0.64 to 1.07)   0.143                                          70 (18 to 97)                                 0.010            0.52   5    0.91 (0.63 to 1.31)    0.601      50 (0 to 92)    0.093      0.13   5    0.65 (0.44 to 0.96)   0.030      67 (12 to 97)   0.016      0.99   Less credible

  *ESR2*             rs928554       2574 vs 2977 (3)           3               1.09 (1.01 to 1.18)   0.025                                          0 (0 to 89)                                   0.743            0.35   3    1.12 (0.97 to 1.29)    0.118      0 (0 to 93)     0.590      0.36   3    1.13 (1.01 to 1.26)   0.041      0 (0 to 89)     0.876      0.57   Less credible

  *HPGD*             rs8752         3968 vs 4830 (3‡)          3               1.05 (0.92 to 1.21)   0.467                                          80 (23 to 99)                                 0.007            0.20   3    1.12 (1.00 to 1.26)    0.047      6 (0 to 97)     0.345      0.53   3    1.03 (0.83 to 1.29)   0.786      83 (34 to 99)   0.003      0.10   Less credible

  *LIPC*             rs6083         7667 vs 7980 (4‡)          4               0.96 (0.90 to 1.02)   0.172                                          41 (0 to 95)                                  0.167            0.23   4    0.89 (0.80 to 0.99)    0.033      22 (0 to 94)    0.278      0.68   4    0.98 (0.91 to 1.05)   0.519      11 (0 to 92)    0.340      0.10   Less credible

  *miR*              rs2292832      2355 vs 2571 (5‡)          5               0.94 (0.86 to 1.02)   0.152                                          0 (0 to 82)                                   0.650            0.17   5    1.06 (0.89 to 1.27)    0.522      0 (0 to 73)     0.789      0.10   5    0.87 (0.78 to 0.98)   0.021      0 (0 to 88)     0.704      0.68   Less credible

  *MSH2*             rs4608577      4308 vs 4011 (3‡)          3               0.94 (0.86 to 1.02)   0.112                                          0 (0 to 91)                                   0.795            0.19   3    0.72 (0.56 to 0.92)    0.008      0 (0 to 95)     0.648      0.68   3    0.96 (0.88 to 1.05)   0.406      0 (0 to 62)     0.945      0.14   Less credible

  *MSH3*             rs184967       8151 vs 10 103 (4‡)        4               1.08 (1.00 to 1.16)   0.049                                          35 (0 to 98)                                  0.204            0.47   4    1.23 (1.02 to 1.49)    0.031      0 (0 to 91)     0.702      0.59   4    1.07 (0.99 to 1.16)   0.098      28 (0 to 98)    0.242      0.54   Less credible

  *MSH3*             rs26779        6050 vs 8024 (6‡)          6               1.07 (1.02 to 1.14)   0.013                                          11 (0 to 92)                                  0.343            0.46   6    1.13 (0.98 to 1.31)    0.085      36 (0 to 93)    0.166      0.59   6    1.08 (1.01 to 1.15)   0.030      0 (0 to 85)     0.682      0.62   Less credible

  *MTHFD1*           rs1950902      9059 vs 11 358 (7‡)        7               0.94 (0.89 to 0.99)   0.026                                          3 (0 to 82)                                   0.400            0.39   7    1.01 (0.87 to 1.18)    0.878      0 (0 to 91)     0.767      0.05   7    0.92 (0.86 to 0.98)   0.015      15 (0 to 90)    0.313      0.79   Less credible

  *PARP1*            rs1136410      7002 vs 8328 (7‡)          7               1.05 (0.95 to 1.17)   0.300                                          52 (0 to 98)                                  0.052            0.24   7    1.23 (1.05 to 1.44)    0.012      0 (0 to 92)     0.475      0.78   7    1.03 (0.93 to 1.15)   0.529      36 (0 to 94)    0.153      0.14   Less credible

  *PGR*              rs1042838      5232 vs 5733 (4‡)          4               1.08 (1.01 to 1.16)   0.034                                          0 (0 to 95)                                   0.507            0.32   4    0.97 (0.77 to 1.23)    0.819      0 (0 to 85)     0.880      0.06   4    1.11 (1.02 to 1.21)   0.012      0 (0 to 96)     0.450      0.71   Less credible

                     rs4951039      13 791 vs 14 288 (7‡)      7               0.91 (0.81 to 1.02)   0.106                                          81 (49 to 95)                                 1.48E-05         0.79   7    0.78 (0.66 to 0.93)    0.005      0 (0 to 68)     0.620      0.82   7    0.91 (0.80 to 1.04)   0.163      82 (51 to 96)   9.30E-06   0.94   Less credible

  *SCD*              rs7849         2011 vs 2580 (3)           3               0.85 (0.73 to 0.98)   0.025                                          29 (0 to 98)                                  0.247            0.53   3    0.64 (0.40 to 1.02)    0.058      41 (0 to 99)    0.185      0.68   3    0.85 (0.71 to 1.02)   0.084      33 (0 to 99)    0.225      0.72   Less credible

  *XPC*              rs2228000      2677 vs 4253 (6)           6               0.99 (0.71 to 1.36)   0.929                                          94 (82 to 99)                                 1.35E-16         0.05   6    0.95 (0.49 to 1.81)    0.866      91 (71 to 99)   2.18E-10   0.09   6    0.58 (0.41 to 0.82)   0.002      92 (83 to 99)   1.49E-11   1.00   Less credible

  *VEGF*             rs699947       4497 vs 5334 (10‡)         10              1.09 (1.00 to 1.19)   0.056                                          46 (0 to 91)                                  0.053            0.56   10   1.14 (1.01 to 1.29)    0.029      14 (0 to 89)    0.317      0.74   10   1.09 (0.95 to 1.24)   0.219      47 (0 to 87)    0.047      0.50   Less credible

  *IGF1*             rs35767        2792 vs 4988 (3)           3               0.95 (0.80 to 1.14)   0.599                                          59 (0 to 99)                                  0.087            0.15   3    0.75 (0.62 to 0.91)    0.003      0 (0 to 97)     0.567      0.79   3    0.98 (0.79 to 1.21)   0.826      60 (0 to 99)    0.081      0.07   Less credible

  *NAT2*             rs1799929      1861 vs 1952 (5\*)         5               0.84 (0.74 to 0.95)   0.004                                          20 (0 to 94)                                  0.289            0.53   5    0.68 (0.47 to 0.99)    0.044      68 (14 to 98)   0.015      0.81   5    0.85 (0.74 to 0.97)   0.016      0 (0 to 85)     0.872      0.61   Less credible

  *NAT2*             rs1799930      6446 vs 7193 (8\*)         8               1.07 (0.99 to 1.16)   0.099                                          44 (0 to 96)                                  0.082            0.25   8    0.99 (0.88 to 1.12)    0.897      0 (0 to 64)     0.812      0.08   8    1.13 (1.00 to 1.27)   0.043      51 (0 to 97)    0.045      0.70   Less credible

  *ABCB1* (*MDR1*)   rs9282564      9536 vs 9145 (6‡)          6               1.07 (1.00 to 1.14)   0.053                                          0 (0 to 77)                                   0.561            0.29   6    0.88 (0.65 to 1.19)    0.424      18 (0 to 86)    0.299      0.14   6    1.09 (1.01 to 1.17)   0.018      0 (0 to 70)     0.729      0.65   Less credible

  *ABCB1* (*MDR1*)   rs1045642      7537 vs 8396 (16)          16              0.94 (0.88 to 1.01)   0.108                                          46 (1 to 88)                                  0.024            0.50   16   0.89 (0.81 to 0.97)    0.012      18 (0 to 78)    0.248      0.87   16   0.97 (0.85 to 1.10)   0.608      57 (32 to 91)   0.003      0.14   Less credible

  *ABCB1* (*MDR1*)   rs1202168      7000 vs 6485 (5)           5               1.06 (0.99 to 1.14)   0.071                                          45 (0 to 93)                                  0.124            0.39   5    1.04 (0.95 to 1.14)    0.350      0 (0 to 81)     0.699      0.14   5    1.12 (1.00 to 1.24)   0.042      52 (0 to 93)    0.080      0.88   Less credible

  *ADIPOR1*          rs1342387      2472 vs 2848 (5‡)          5               0.87 (0.78 to 0.98)   0.018                                          48 (0 to 95)                                  0.105            0.71   5    0.84 (0.73 to 0.96)    0.012      0 (0 to 62)     0.900      0.68   5    0.85 (0.69 to 1.03)   0.098      63 (0 to 96)    0.029      0.79   Less credible

  *AXIN2*            rs2240308      4723 vs 4932 (4‡)          4               1.06 (1.00 to 1.12)   0.044                                          0 (0 to 92)                                   0.397            0.30   4    1.07 (0.96 to 1.19)    0.219      17 (0 to 95)    0.306      0.29   4    1.10 (1.01 to 1.21)   0.037      0 (0 to 76)     0.758      0.54   Less credible

  *MMP1*             rs1799750      1660 vs 2024 (10)          9               0.78 (0.66 to 0.93)   0.005                                          59 (8 to 88)                                  0.012            0.95   9    0.78 (0.61 to 0.99)    0.041      21 (0 to 68)    0.254      0.75   10   0.70 (0.56 to 0.88)   0.002      57 (9 to 88)    0.013      1.00   Less credible

  *CYP1A1*           rs1048943      9661 vs 11 774 (19\*)      19              1.28 (1.07 to 1.52)   0.006                                          84 (83 to 96)                                 1.15E-15         1.00   18   1.26 (1.04 to 1.52)    0.016      0 (0 to 55)     0.456      0.72   19   1.36 (1.08 to 1.72)   0.009      88 (93 to 98)   2.16E-23   1.00   Less credible

  *GSTT1*            Null variant   19 133 vs 27 821 (56)      7               0.91 (0.70 to 1.20)   0.508                                          71 (21 to 99)                                 0.015            0.49   53   1.17 (1.07 to 1.28)    0.001      70 (71 to 90)   1.62E-15   1.00   6    1.00 (0.73 to 1.37)   0.979      53 (0 to 98)    0.059      0.05   Less credible

  *VDR*              rs1544410      14 789 vs 15 922 (16‡)     16              0.83 (0.72 to 0.96)   0.011                                          93 (91 to 95)                                 5.59E-40         1.00   16   0.81 (0.67 to 0.98)    0.033      85 (77 to 89)   1.08E-14   1.00   16   0.82 (0.69 to 0.96)   0.015      88 (83 to 91)   2.62E-20   1.00   Less credible

  *8q24*             rs6983267      51 730 vs 53 589 (34‡)     34              1.11 (1.06 to 1.17)   1.75E-05                                       85 (77 to 93)                                 1.93E-28         1.00   34   1.16 (1.08 to 1.25)    4.92E-05   79 (66 to 89)   2.80E-18   1.00   34   1.16 (1.08 to 1.24)   2.98E-05   80 (69 to 92)   8.68E-19   1.00   Less credible

  *RAD18*            rs373572       6560 vs 6906 (5‡)          5               1.15 (1.01 to 1.30)   0.031                                          75 (33 to 98)                                 0.003            0.96   5    1.23 (1.01 to 1.49)    0.041      54 (0 to 95)    0.067      0.93   5    1.15 (0.98 to 1.36)   0.080      73 (21 to 98)   0.005      0.98   Less credible

  *NQ01*             rs1800566      11 183 vs 12 525 (16‡)     16              1.17 (1.05 to 1.30)   0.006                                          80 (66 to 94)                                 1.17E-09         1.00   16   1.21 (0.99 to 1.48)    0.060      55 (17 to 87)   0.004      0.91   16   1.20 (1.06 to 1.37)   0.006      78 (64 to 94)   8.77E-09   1.00   Less credible

  *PTGS2*/*COX2*     rs20417        7785 vs 11 371 (18)        17              1.10 (1.00 to 1.2)    0.035                                          37 (0 to 83)                                  0.062            0.57   17   1.24 (1.04 to 1.47)    0.016      0 (0 to 46)     0.928      0.64   18   1.12 (1.00 to 1.26)   0.050      51 (14 to 87)   0.019      0.90   Less credible

  *NOD2*             rs2066844      3297 vs 3088 (9)           9               1.38 (1.04 to 1.84)   0.026                                          39 (0 to 91)                                  0.109            0.66   9    1.97 (0.55 to 7.04)    0.299      0 (0 to 83)     0.689      0.17   9    1.35 (1.02 to 1.78)   0.033      33 (0 to 90)    0.155      0.86   Less credible

  *CCND1*            rs17852153     6500 vs 8885 (20)          20              1.10 (1.02 to 1.19)   0.019                                          58 (45 to 92)                                 0.001            0.83   20   1.11 (0.97 to 1.28)    0.128      63 (54 to 94)   7.69E-05   0.82   20   1.15 (1.05 to 1.26)   0.003      18 (0 to 76)    0.226      0.94   Less credible

  *GSTM1*            Null variant   28 240 vs 38 880 (74)      13              1.12 (0.89 to 1.40)   0.335                                          70 (22 to 98)                                 0.005            1.00   6    1.18 (0.90 to 1.55)    0.234      67 (0 to 98)    0.028      1.00   74   1.10 (1.05 to 1.16)   0.001      47 (34 to 75)   6.63E-06   1.00   Less credible

  *9p24*             rs719725       13 513 vs 14 999 (14)      14              1.07 (1.02 to 1.11)   0.002                                          24 (0 to 79)                                  0.190            0.79   14   1.09 (1.02 to 1.15)    0.006      29 (0 to 75)    0.148      0.94   14   1.09 (1.02 to 1.17)   0.008      0 (0 to 66)     0.521      0.72   Less credible

  *ERCC5*            rs17655        9653 vs 11 367 (14)        13              1.07 (1.02 to 1.12)   0.003                                          0 (0 to 73)                                   0.626            0.60   13   0.98 (0.89 to 1.08)    0.688      0 (0 to 77)     0.538      0.07   14   1.14 (1.04 to 1.24)   0.004      44 (0 to 85)    0.038      1.00   Less credible

  *GH1*              rs2665802      3275 vs 3848 (7)           7               0.89 (0.80 to 0.99)   0.025                                          49 (0 to 97)                                  0.069            0.68   7    0.83 (0.71 to 0.98)    0.028      37 (0 to 95)    0.144      0.87   7    0.89 (0.78 to 1.02)   0.103      36 (0 to 96)    0.157      0.62   Less credible

  *TP73*             G4C14          858 vs 1173 (4)            4               1.21 (1.04 to 1.40)   0.013                                          4 (0 to 92)                                   0.371            0.46   4    1.75 (1.23 to 2.48)    0.002      0 (0 to 94)     0.513      0.91   4    1.10 (0.83 to 1.45)   0.501      55 (0 to 96)    0.083      0.18   Less credible

  *TGFB1*            rs4803455      3747 vs 4513 (3‡)          3               1.11 (1.04 to 1.18)   0.001                                          0 (0 to 71)                                   0.903            0.66   3    1.12 (1.01 to 1.24)    0.027      0 (0 to 80)     0.845      0.59   3    1.18 (1.06 to 1.30)   0.001      0 (0 to 85)     0.879      0.90   Less credible

  *APC*              rs1801155      2389 vs 4223 (5)           5               1.60 (1.21 to 2.11)   0.001                                          27 (0 to 94)                                  0.244            0.85   na   na                     na         na              na         na     5    1.62 (1.21 to 2.16)   0.001      28 (0 to 94)    0.235      0.99   Less credible

  *MLH1*             rs63750447     937 vs 812 (4)             3               2.14 (1.12 to 4.10)   0.022                                          39 (0 to 99)                                  0.194            0.75   na   na                     na         na              na         na     3    2.17 (1.14 to 4.14)   0.019      36 (0 to 98)    0.208      0.96   Less credible

  *VDR*              rs11568820     4001 vs 4682 (5\*)         4               1.14 (1.05 to 1.23)   0.001                                          0 (0 to 92)                                   0.648            0.71   4    1.37 (1.02 to 1.85)    0.039      35 (0 to 97)    0.203      0.90   5    1.14 (1.04 to 1.24)   0.004      0 (0 to 0)      0.989      0.85   Less credible

  *ABCB1* (*MDR1*)   rs1128503      246 vs 399 (3)             3               0.70 (0.51 to 0.96)   0.027                                          45 (0 to 98)                                  0.164            0.59   3    0.77 (0.37 to 1.59)    0.483      71 (0 to 99)    0.031      0.31   3    0.52 (0.35 to 0.76)   0.001      0 (0 to 96)     0.617      0.93   Less credible

  *ADIPOQ*           rs2241766      1517 vs 1909 (5)           5               1.17 (1.01 to 1.35)   0.033                                          29 (0 to 97)                                  0.231            0.50   5    1.04 (0.74 to 1.45)    0.830      14 (0 to 98)    0.325      0.06   5    1.26 (1.09 to 1.47)   0.002      8 (0 to 96)     0.364      0.92   Less credible

  *CHEK2*            rs1787996      1687 vs 3370 (3)           3               1.47 (1.12 to 1.92)   0.006                                          0 (0 to 98)                                   0.499            0.53   na   na                     na         na              na         na     3    1.48 (1.13 to 1.95)   0.005      0 (0 to 98)     0.496      0.81   Less credible

  *CHEK2*            1100delC       2417 vs 3615 (4)           4               1.66 (1.01 to 2.73)   0.048                                          0 (0 to 83)                                   0.835            0.60   na   na                     na         na              na         na     4    1.66 (1.01 to 2.75)   0.047      0 (0 to 83)     0.835      0.86   Less credible

  *TP53*             rs1042522      10591 vs 12 673 (30)       30              1.11 (0.99 to 1.24)   0.077                                          85 (84 to 95)                                 4.42E-26         0.73   30   1.21 (1.02 to 1.44)    0.026      70 (55 to 88)   2.77E-09   0.98   30   1.11 (0.96 to 1.28)   0.163      82 (84 to 05)   7.58E-20   0.64   Less credible

  *TP53*             rs17878362     1812 vs 2319 (6)           6               0.98 (0.76 to 1.26)   0.859                                          70 (23 to 96)                                 0.005            0.06   6    1.28 (0.81 to 2.03)    0.282      0 (0 to 79)     0.638      0.22   6    0.95 (0.71 to 1.27)   0.734      71 (25 to 96)   0.004      0.40   Less credible

  *KRAS*             rs712          1982 vs 2194 (3)           3               1.22 (0.86 to 1.72)   0.270                                          90 (55 to 100)                                6.87E-05         0.19   3    1.72 (0.73 to 4.06)    0.215      87(44 to 100)   3.74E-04   0.16   3    1.17 (0.84 to 1.65)   0.350      83 (32 to 99)   0.003      0.28   Less credible

  *ARLTS1*           rs3803185      2281 vs 3196 (5†)          5               1.09 (1.01 to 1.18)   0.026                                          0 (0 to 76)                                   0.803            0.35   5    1.08 (0.90 to 1.29)    0.432      43 (0 to 93)    0.133      0.21   5    1.18 (0.95 to 1.46)   0.131      62 (0 to 96)    0.032      0.77   Less credible

  *1q32.1*           rs4951291      15 835 vs 16 724 (9‡)      9               0.91 (0.84 to 0.99)   0.021                                          68 (22 to 88)                                 0.002            0.85   9    0.74 (0.62 to 0.87)    2.72E-04   0 (0 to 69)     0.616      0.95   9    0.92 (0.83 to 1.01)   0.077      72 (30 to 90)   4.33E-04   0.91   Less credible

  *PPAR-gamma*       rs9858822      2152 vs 2630 (5)           4               1.40 (1.19 to 1.65)   4.69E-05                                       0 (0 to 98)                                   0.697            0.96   2    1.69 (1.19 to 2.39)    0.003      0 (0 to 98)     0.801      0.54   4    1.47 (1.19 to 1.83)   4.55E-04   0 (0 to 98)     0.618      1.00   Less credible

  *DNMT3B*           rs1569686      1224 vs 1381 (5)           4               0.57 (0.47 to 0.68)   1.81E-09                                       0 (0 to 0)                                    0.992            1.00   4    0.93 (0.54 to 1.58)    0.775      0 (0 to 97)     0.414      0.06   5    0.46 (0.36 to 0.59)   2.40E-09   30 (0 to 95)    0.223      1.00   Less credible

  *NOD2*             rs2066847      4573 vs 3733 (10)          10              1.39 (1.16 to 1.66)   3.21E-04                                       0 (0 to 71)                                   0.547            0.78   10   2.36 (0.69 to 8.13)    0.173      0 (0 to 76)     0.720      0.31   10   1.38 (1.14 to 1.66)   0.001      0 (0 to 74)     0.488      0.96   Less credible
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Includes GWAS data from Ontario.

†Tomlinson 2008 was based on 10 samples.

‡Includes GWAS data from SOCCS.

GWASs, genome-wide association studies; SOCCS, Study of CRC in Scotland.

Polymorphisms classified as either 'positive' or 'less-credible positive' SNPs were sent for validation in synthesised data from the GECCO, CORECT and CCFR consortia. Validation was only able to be performed for 68 out of 77 polymorphisms, as one 'positive' variant (rs34612342 in *MUTYH \[Y179C\]* gene) was dropped due to its low imputation quality in these GWASs; 5 'less-credible positive' polymorphisms (in *GSTT1*, *GSTM1*, *TP73*, *CHEK2* and *CYP2E1*) had no rs numbers; and 3 polymorphisms (in *TP53* and *KRAS*) were not available in these GWASs; therefore, they were not able to be validated. Of the 17 'positive' SNPs sent for validation, 7 polymorphisms (41.2%) in 6 different loci (rs12953717 and rs4464148 in *SMAD7,* rs355527 in *BMP2,* rs10505477 in *8q24,* rs961253 in *20p12.3,* rs16892766 in *8q23.3,* rs3802842 in *11q23.1*) reached a genome-wide statistical significance (p≤5×10^−8^) in at least one meta-analysis model and 6 polymorphisms (35.3%) in 6 different loci (rs7259371 in *RHPN2,* rs2736100 in *TERT,* rs10795668 in *10p14,* rs36053993 in *MUTYH,* rs1862748 in *CDH1* and rs1800469 in *TGFB1*) reached a nominally statistical significance (p\<0.05) in at least one meta-analysis model. However, the remaining 4 polymorphisms (23.5%) in 4 different loci (rs2066847 in *NOD2,* rs1569686 in *DNMT3B,* rs9858822 in *PPAR-gamma* and rs4951291 in *1q32.1*) failed in the GWAS validation of all genetic models ([online supplementary tables 5--7](#SP2){ref-type="supplementary-material"}) and they were therefore downgraded to 'less-credible positive'. Of the 51 'less-credible positive' SNPs sent for validation, 2 polymorphisms (3.9%) in 2 different loci (rs6983267 in 8q24 and rs1801155 in *APC*) reached a genome-wide statistical significance (p≤5×10^−8^) in at least one meta-analysis model and 11 polymorphisms (21.6%) in 11 different loci (rs1136410 in *PARP1,* rs11568820 in *VDR,* rs1342387 in *ADIPOR1,* rs719725 in *TPD52L3,* rs20417 in *PTGS2/COX2,* rs2665802 in *GH1,* rs4803455 in *TGFB1,* rs7849 in *SCD,* rs8752 in *HPGD,* rs36053993 in *MUTYH* and rs928554 in *ESR2*) reached a nominally statistical significance (p\<0.05) in at least one meta-analysis model, whereas the remaining 38 polymorphisms (74.5%) failed in the GWAS validation of all genetic models ([online supplementary tables 5--7](#SP2){ref-type="supplementary-material"}). Overall, 26 (33.8%) out of the 77 nominally significant polymorphisms tested via meta-analysis were successfully validated in these GWASs (p\<0.05).

Funnel plots were produced for all 'credible' ([online supplementary figures 1--14](#SP3){ref-type="supplementary-material"}) and 'less-credible' SNPs ([online supplementary figures 15--77](#SP3){ref-type="supplementary-material"}) for their summary estimates in allelic model. Small study effects were reported for 2 (14.3%) of the 14 'positive' polymorphisms (rs36053993 in *MUTYH* and rs4464148 in *SMAD7*) and for 10 (15.9%) of 63 'less-credible' polymorphisms (rs1229984 in *ADH1B*, rs25487 in *XRCC1*, rs2240308 in *AXIN2*, rs1799750 in *MMP1*, rs1048943 in *CYP1A1*, rs373572 in *RAD18*, rs1800566 in *NQ01*, rs2066844 in *NOD2*, rs2665802 in *GH1*, rs712 in *KRAS*). Therefore, their reported association with CRC risk should be interpreted with caution.
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The remaining 231 polymorphisms (75.0%) assessed in meta-analyses were reported to have no statistically significant association (p\>0.05) with CRC risk in all three genetic models ([online supplementary table 9](#SP2){ref-type="supplementary-material"}), based on accrued data on 192 to 21 929 cases and 251 to 24 054 controls, with median of at least 4017 cases per meta-analysis. Of them, 148 polymorphisms were classified as having negative associations with CRC risk because the number of cases was less than 5000 for which the null results could be due to limited statistical power, while another 83 SNPs with p\>0.05 and the number of cases\>5000 were classified as null variants with adequate statistical power ([online supplementary table 9](#SP2){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This systematic, comprehensive field synopsis of genetic association studies on CRC updates the two previous field synopses[@R10] with application of harmonised methods for evidence appraisal and further validation of the identified genetic associations in three GWAS consortia. Specifically, we extracted and collated data for 1063 polymorphisms in 303 different genes from 869 publications and performed up-to-date meta-analyses for 308 variants in 158 different genes that had data from at least three independent studies available for analysis. After credibility assessment and validation, we identified a total of 12 genetic loci credibly associated with CRC risk, of which 6 loci (*MUTYH, SMAD7,* 8q24, 8q23.3, 11q23.1, 20p12.3) were also classified as credibly associated with CRC risk in the previous field synopses and the other 6 loci (*TGFB1, TERT, CDH1, RHPN2, BMP2* and 10p14) are novel findings as they have not been assessed or reported as credible risk loci in the previous field synopses.

We note that a synopsis was undertaken of literature on genetic associations with CRC published in the period 2012--2017.[@R24] Our analysis differs from that study, in that it includes and updates data from our previous field synopses,[@R10] includes data from three GWA studies in the meta-analysis and further validates the findings in three GWA consortia.

Similar to our previous field synopses,[@R10] the present study reported two SNPs at 8q24 locus (rs6983267 and rs10505477) with strong evidence supporting significant associations with CRC risk and with these associations further replicated in three GWAS consortia. In biopsies of the rectum, sigmoid colon and cecum mucosa, proliferation has been reported to be higher among homozygotes for the risk alleles of the rs6983267 and rs10505477 variants compared with those with other genotypes in the general population.[@R25] The rs6983267 variant has been assessed as having a highly credible association with colorectal adenomas.[@R26] In fine-mapping and bioinformatic analysis performed within the GECCO-CCFR consortia, the rs6983267 variant was appraised as having a strong functional evidence.[@R28] The rs6983267 may be a somatic target in CRC[@R29] and may be associated with enhanced responsiveness to Wnt signalling.[@R30] Furthermore, rs6983267 has also been found to be associated with other types of cancer, including prostate cancer.[@R31] Interaction with the *MYC* proto-oncogene has been controversial,[@R34] but in functional studies in cell lines, interaction between enhancer elements in the 8q24 locus and the *MYC* promoter, via transcription factor Tcf-4 binding and allele-specific regulation of *MYC* expression, has been demonstrated.[@R38] Expression levels of one of these, *CARLo-5*, in normal colon tissue have been found to be statistically significantly correlated with rs6983267, and chromosome conformation capture analysis of genomic DNA from CRC-derived cell lines provided evidence of physical interaction between the active regulatory region of the *CARLo-5* promoter and the *MYC* enhancer region.[@R39] Since the end of our search period (21 November 2018), an analysis of GWAS data on 22 775 cases and 47 731 controls from 14 studies in East Asia detected a genome-wide significant association with the rs6983267 variant.[@R40] In addition, in a combined meta-analysis of up to 58 131 cases and 67 347 controls from the GECCO, CORECT and CCFR consortia, in which imputed variants from a whole-genome sequencing analysis and Haplotype Reference Consortium panel variants were included, analysis in the 8q24.21 region conditioned on the rs6983267 and rs7013278 variants identified a genome-wide significant association with the rs4313119.[@R41]

Two genetic polymorphisms (rs12953717 and rs4464148) tagging in *SMAD7* were identified to be associated with CRC with highly credible evidence. Associations with rs12953717 and rs4464148 were successfully validated in the three GWAS consortia. In fine-mapping and bioinformatics analysis performed within the GECCO-CCFR consortia, rs4464148 was appraised as having less strong functional evidence than the highly correlated rs9932005 variant, which is located within 5 kb away.[@R28] The SMAD7 protein is an inhibitor for the TGF-ß signalling pathway.[@R42] There were highly credible associations with the rs1862748 (tagging *CDH1*), rs355527 (*BMP2*), rs961253 (*BMP2*) and rs7259371 (*RHPN2*) variants, which are TGF-ß related, and replicated in the data from the GWAS consortia. In the recent East Asian analysis, the association with the rs961253 (*BMP2*) variant was replicated, as well as additional variants of *SMAD7* (rs7229639, rs4939827), *CDH1* (rs9929218), *BMP2* (rs4813802) and *RHPN2* (rs10411210).[@R40] In the analysis from the GECCO, CORECT and CCFR consortia, conditioned on the rs4813802 and rs189583 variants of *BMP2* as well as each other, novel associations with the *BMP2* variants rs28488 and rs994308 were detected.[@R41]

Additionally, two variants (rs34612342 and rs36053993) tagging the *MUTYH* gene were highly credibly associated with increased CRC risk, of which rs36053993 was validated in the three GWAS consortia data, while rs34612342 was not tested due to its poor imputation quality. The *MUTYH* gene is known to be involved in the dysfunction of base-excision repair, which is the major pathway for repairing oxidative damage. This biological pathway in which the *MUTYH* gene is involved contributes to the development of multiple colorectal adenomas and carcinomas (*MUTYH*-associated polyposis (MAP) syndrome).[@R44] In our analysis, the p values were nominally significant for all models for the rs34612342 variant and for the allelic and dominant models for the rs36053993 variant. For the former variant, the magnitude of effect was greatest for the recessive model, although with wide CIs, which is intriguing as MAP, in which highly penetrant mutations are implicated, and is inherited in an autosomal recessive manner.[@R45]

Highly credible associations were also reported for four variants tagging four different genes that are involved in inflammation or immune response. First, a positive association with the rs3802842 variant in the 11q23.1 was identified for CRC risk and this association was replicated in the data from the GWAS consortia and in the recent East Asian analysis.[@R40] Fine-mapping and bioinformatics analysis performed within the GECCO-CCFR consortia support this variant with strong functional evidence.[@R28] Fine mapping identified two genes *COLCA1* and *COLCA2* arranged on opposite strands and sharing a regulatory region containing rs3802842.[@R46] It is reported that carrying the risk allele of rs3802842 is associated with the expression levels of *COLCA1* and *COLCA2,* which is further correlated with lymphocyte infiltration of colonic lamina propia. Further, in an expression quantitative trait locus analysis in colorectal tissue, there were signals for *COLCA1* and *COLCA2*.[@R47] The polymorphism rs10795668 in 10p14 locus tagging *GATA3* gene was reported with a highly credible association with CRC, and this association was further replicated in the GWAS consortia and in the recent East Asian analysis.[@R40] However, in fine-mapping and bioinformatics analysis, this variant presents with weak functional evidence.[@R28] Another less-credible positive association with the rs9858822 variant of *PPARγ* was identified; however, this association was not replicated in the GWAS consortia. Bioinformatics analysis showed that PPARγ and its ligands have been found to block proinflammatory genes in colon cancer cell lines, activated macrophages and monocytes.[@R48] *PPARγ* is also involved in lipid metabolism, adipocyte differentiation, and glucose homeostasis and insulin sensitivity.[@R48] A less-credible positive association also reported one variant (rs2066847) in *NOD2* gene; however, this association was not replicated. Evidence from experimental studies in mice investigating the role of *Nod2* in colorectal tumour risk has also been inconsistent.[@R49] The recent analyses in East Asia,[@R40] the GECCO, CORECT and CCFR consortia[@R41] and of five UK studies and a further 10 from the COGENT consortium[@R47] identified new associations in the major histocompatibility region.

The remaining two variants with highly credible associations with CRC risk included rs2736100 tagging *TERT* and rs16892766 at 8q23.3 tagging *EIF3H*. These variants were all validated in the GWAS consortia datasets. Fine-mapping and bioinformatics analysis performed within the GECCO-CCFR consortia supported these variants with strong functional evidence, for which polymorphism rs2736100 in *TERT* gene has been reported to be associated with telomere length and the risk of different types of cancer and chronic diseases other than cancer.[@R52] For the association with the rs16892766 variant at 8q23.3 tagging *EIF3H*, another variant rs16888589 was previously reported with the lowest p value for the association with CRC in this locus.[@R25] Functional analysis and chromosome conformation capture analysis in CRC cell lines have found that the genomic region harbouring rs16888589 increases *EIF3H* expression,[@R53] but analysis of expression quantitative trait loci around rs16892766 suggested that *UTP23* rather than *EIF3H* is the target of genetic variation associated with CRC in this region.[@R54]

The less credible associations with 63 variants of 52 genes involved the following pathways---adhesion (*AXIN2*, *MMP1*); alcohol metabolism (*ADH1B*); angiogenesis (*VEGF*); blood clotting (*SERPINE1*); DNA repair (*CHEK2, ERCC5, MSH2, MSH3, PARP1, RAD18, XPC, XRCC1*); hormone metabolism (*ESR2, GH1, PGR*); inflammation and immune response (*CRP, HPGD, PTGS2/COX2*); inhibition of cell growth (*CCND1, EGF, TGFB1*); iron metabolism (*HFE*); lipid metabolism (*ADIPOQ, ADIPOR1, LIPC, SCD*); one-carbon metabolism (*MTHFR*, *MTFD1, MTRR*); substrate metabolism (*ABCB1; CYP1A1, CYP2C9, CYP2E1, GSTM1, GSTT1, NAT2, NQ01*); tumour suppression (*ARLTS1, miR, TP73*); vitamin D metabolism (*VDR*)---common low penetrance variants at 1q32.1 (rs4951039, *LINC00303*) and 9p24 (rs719725); and the common rs1801155 (I1307K) variant of *APC,* for which large numbers of rare variants have been identified,[@R55] and rs63750447 (V384D) variant of *MLH1*, for which rare variants confer a high risk of Lynch syndrome.[@R56] These variants were classified as less-credible SNPs because of either the substantial heterogeneity or the high possibility of false positive; however, we would like to highlight a number of less-credible genetic loci (*PARP1, MYC, VDR, ADIPOR1, APC, PTGS2/COX2, SCD, HPGD* and *ESR2*), which were replicated in the GWAS data and for which their linked pathways are worthy of further investigation in future studies.

Updating field synopses is challenging because genetic analysis is such a fast-moving field. Recent trends highlighted by three articles published since we completed our search in November 2018 include the extension of consortia to increase statistical power to detect and replicate associations,[@R47] the investigation of populations other than of European origin,[@R40] and the use of whole-genome sequencing and more comprehensive reference panels to extend the range of genetic variants considered to include those that are rare or of low frequency.[@R41] These three articles have added new loci for CRC susceptibility and indicate that most of the risk loci previously associated with CRC in populations of European origin are also associated with CRC risk in East Asian populations.

We checked whether the 14 variants we classified as 'highly credible' were replicated in the paper of Law *et al*.[@R47] For one variant, rs34612342 *MUTYH*, there was poor imputation quality. However, as there was no satisfactory proxy for this, we report the available information, which supported the association (p=0.029). All the remaining 13 variants had p values for association less than 5.0×10^−5^ with no more than moderate heterogeneity. Such an empirical comparison was not appropriate with the data of Huyghe *et al* [@R41] because of the considerable overlap of included participants.

In summary, we have conducted a comprehensive study to capture and meta-analyse all SNP data for common genetic variants. The analysis clearly identifies 14 variants at 12 loci for which there is robust evidence of their impact on CRC risk, 63 variants at 52 loci for which further evidence through international collaboration should be generated and 231 variants for which the overall evidence does not support any association with CRC risk. With increasing availability of data from multiple SNPs, it is clear that studies to test associations must achieve very high levels of statistical stringency. Nonetheless, the analysis here provides a resource for mining available data and puts into context the sample sizes required for the identification of true associations for common genetic variants. Future resequencing studies are expected to identify rarer variants (eg, prevalence 0.05%--5%) with intermediate or perhaps even large effects, and GWAS of structural variation will likely identify deletions, amplifications and other copy number variations that may also influence CRC risk.[@R6] This study highlights a number of common genetic variants that could be incorporated into genetic risk-prediction algorithms as further risk factors are identified and highlights the loci at which further research effort should be targeted. All data are available from the CRCgene2 database.
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